1.Date of occurrence of the event:2023/03/13
2.Company name: OBI Pharma Inc.
3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):Head office
4.Reciprocal shareholding ratios: N/A
5.Cause of occurrence:
To coordinate with the business needs of Obigen Pharma Inc. (hereinafter referred to as “Obigen”), and in accordance with related laws and regulations for TWSE/TPEx Listed Companies, the Company shall be able to disperse its shareholding of Obigen at once or in stages before Obigen’s IPO by methods as follows:
(1)Forfeit the subscription rights of Obigen’s cash capital increase
The issue price of Obigen’s cash capital increase should be no less than the latest audited book value per share resolved by the Board of Directors. Considering the business needs of Obigen and to attract and retain professional talents, except for the 10%~15% of new shares reserved for employees who are eligible, the Company shall be able to forfeit the subscription rights of cash capital increase and request Obigen to distribute the rights to OBI’s shareholders. The Board of Directors of Obigen will set all matters related to issue price
, contacting specific persons, and procedures depending on market and operating conditions.
(2)Share dispersal coordinating with Obigen’s application for the trading of emerging stocks or the listing of securities on the TWSE/TPEx
The Company should allocate the shares for underwriter to subscribe and exercise the over-alloment in accordance with related laws and regulations for Emerging Stock and TWSE/TPEx Listed Companies. The Company and the underwriter will negotiate on the amount of shares allocated and the issue price depending on related laws and regulations for TWSE/TPEx Listed Companies, market conditions, and Obigen’s operating conditions.
6.Countermeasures:
The above-mentioned matters related to the forfeiture of subscription of Obigen’s cash capital increase and shareholding dispersal is proposed for general shareholders’ meeting authorization for the Board of Directors to deal with subsequent procedures.
7.Any other matters that need to be specified(the information disclosure also meets the requirements of Article 7, subparagraph 9 of the Securities and Exchange Act Enforcement Rules, which brings forth a significant impact on shareholders rights or the price of the securities on public companies.):None